Press releases
Global Bio-India 2023 set to reinforce strategic collaboration between India and the UK in biotechnology innovation
• From $92.3 Bn to $300 Bn: GBI 2023 Sets the Stage for India's Biotech Meteoric Rise and attracts global interest from companies, academia and start-ups
• Leading biotech giants converge in India, marking a historic collaboration that positions the Global Bio-India 2023 event as a platform for international biotech partnerships.
London, 4 December 2023 - The Global Bio-India 2023 event organised by the Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India, and its Public Sector Undertaking, Biotechnology Industry Research Assistance Council (BIRAC), is set to take place from 4-6 December 2023, India. Global Bio-India 2023 will be the largest congregation of biotech startups and the central theme of the conference is Biotech Innovation and Bio-manufacturing.
With the Indian biotech industry reaching $92.3 billion in 2022 and targeting an impressive $150 billion by 2025 and $300 billion by 2030, the event invites individuals and companies worldwide to participate and establish their innovative practices in a thriving market driven by escalating demand both domestically and internationally. Global Bio-India 2023 is not just an event; it's an opportunity to shape the future of biotechnology on a global scale.
The global biotech market estimated at USD one trillion in 2022 and projected to grow at a CAGR of 7.4 per cent to 15.6 per cent from 2023 to 2030 (Source). In the UK, the biotechnology industry revenue is estimated to reach £21.8bn by 2024, and the market size is projected to increase over the next five years.
This year’s £16 million investment from UK Research and Innovation (UKRI), matched by the Government of India, is a testament to the strong relationship between the UK and India and their commitment to innovation (Source). As Prime Minister Rishi Sunak aims to turn the UK into a science superpower, biotechnology is indeed playing a pivotal role.
The conference will bring together stakeholders from across the world, such as regulatory bodies, government players, SMEs, large industries, bio clusters, research institutes, investors and the start-up ecosystem. With a focus on biosafety, ethics and inclusive growth, the event benefits global stakeholders in life sciences, healthcare, industrial biotech, agri-tech, med-tech and clean energy. Global attendees can expect opportunities for business growth and meaningful dialogues with policymakers.
Global Bio-2023 will see representation from over 30+ countries thus emerging as one of the biggest networking events connecting India’s biotech network with the global community.
Prof. Andrew Hopkins, Chief Executive, Exscientia, Oxford; the British Deputy High Commissioner; Mr. Sunil Shah, CEO, o2h Ventures, Cambridge; Dr Alex Cole, Director of Market Strategy, CPI; and Mr Derek Sear, Engagement and Partnerships Manager, WMHTIA (West Midlands Health Tech Innovation Accelerator) - University of Birmingham, Mr. Daniel Enrique Zamora Gracia, Programme Director-Health Innovation Accelerator, Health Innovation Manchester - an England's NHS organisation, UK will be participating and offering a unique perspective on the future of biotechnology. Some of the topics that will be addressed during the conference are ‘Accelerate Biotech Innovations and deliver biotech products for sustainable future under the session’, ‘Preparing for the next pandemic’, 'Biomanufacturing’ and ‘Advancing biologics product development’.
Hon’ble Union Minister of State (Independent Charge) Science & Technology, MoS PMO, Personnel, Public Grievances, Pensions, Atomic Energy and Space, Dr Jitendra Singh said “This event underscores India's imminent entry into the league of global leaders in biotechnology. The global significance of this event highlights the government's determination to attract international players to invest in India, fostering increased foreign direct investment in the pharmaceutical and biotech sectors. India is resolute in its commitment to assume a leadership role in the field of biotechnology”.
Dr Rajesh S Gokhale, Secretary, Department of Biotechnology (DBT) said, ‘Global Bio-India 2023 serves as a platform for innovation, where participants can explore, ideate and shape the future of the biotechnology industry. I believe this event will be a testament to our shared commitment to advancing science, improving lives and building a sustainable and inclusive future for all’.
Speaking about how the event is set to bring the global biotechnology industry together, Dr Jitendra Kumar, Managing Director, BIRAC said, ‘As we kick off Global Bio-India 2023, we envision a collaborative platform that offers an opportunity for all biotech stakeholders - from entrepreneurs and scientists to business and R&D professionals - come together to discuss the latest advancements in biotechnology. With the Indian biotech industry set to reach $150 billion by 2025 and an ambitious $300 billion by 2030, the event calls on individuals and companies worldwide to participate and establish innovative practices in a thriving market driven by escalating demand. It serves as a central point for international participants to share their thoughts on biotech innovations, biomanufacturing, AI and big data in life sciences and biotech, biopharma and emerging agri-technologies’ .
About DBT
The Department of Biotechnology (DBT), Ministry of Science and Technology, boosts and augments the development of biotechnology ecosystem in India, through its expansion and application in agriculture, healthcare, animal sciences, environment, and industry.
About BIRAC
Biotechnology Industry Research Assistance Council (BIRAC) is a not-for-profit Section 8, Schedule B, Public Sector Enterprise set up by Department of Biotechnology (DBT), Government of India, as an interface agency to strengthen and empower emerging biotech enterprises to undertake strategic research and innovation, addressing nationally relevant product development needs.
For Media Queries:
Contact Gutenberg at birac@thegutenberg.com
• From $92.3 Bn to $300 Bn: GBI 2023 Sets the Stage for India's Biotech Meteoric Rise and attracts global interest from companies, academia and start-ups
• Leading biotech giants converge in India, marking a historic collaboration that positions the Global Bio-India 2023 event as a platform for international biotech partnerships.
London, 4 December 2023 - The Global Bio-India 2023 event organised by the Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India, and its Public Sector Undertaking, Biotechnology Industry Research Assistance Council (BIRAC), is set to take place from 4-6 December 2023, India. Global Bio-India 2023 will be the largest congregation of biotech startups and the central theme of the conference is Biotech Innovation and Bio-manufacturing.
With the Indian biotech industry reaching $92.3 billion in 2022 and targeting an impressive $150 billion by 2025 and $300 billion by 2030, the event invites individuals and companies worldwide to participate and establish their innovative practices in a thriving market driven by escalating demand both domestically and internationally. Global Bio-India 2023 is not just an event; it's an opportunity to shape the future of biotechnology on a global scale.
The global biotech market estimated at USD one trillion in 2022 and projected to grow at a CAGR of 7.4 per cent to 15.6 per cent from 2023 to 2030 (Source). In the UK, the biotechnology industry revenue is estimated to reach £21.8bn by 2024, and the market size is projected to increase over the next five years.
This year’s £16 million investment from UK Research and Innovation (UKRI), matched by the Government of India, is a testament to the strong relationship between the UK and India and their commitment to innovation (Source). As Prime Minister Rishi Sunak aims to turn the UK into a science superpower, biotechnology is indeed playing a pivotal role.
The conference will bring together stakeholders from across the world, such as regulatory bodies, government players, SMEs, large industries, bio clusters, research institutes, investors and the start-up ecosystem. With a focus on biosafety, ethics and inclusive growth, the event benefits global stakeholders in life sciences, healthcare, industrial biotech, agri-tech, med-tech and clean energy. Global attendees can expect opportunities for business growth and meaningful dialogues with policymakers.
Global Bio-2023 will see representation from over 30+ countries thus emerging as one of the biggest networking events connecting India’s biotech network with the global community.
Prof. Andrew Hopkins, Chief Executive, Exscientia, Oxford; the British Deputy High Commissioner; Mr. Sunil Shah, CEO, o2h Ventures, Cambridge; Dr Alex Cole, Director of Market Strategy, CPI; and Mr Derek Sear, Engagement and Partnerships Manager, WMHTIA (West Midlands Health Tech Innovation Accelerator) - University of Birmingham, Mr. Daniel Enrique Zamora Gracia, Programme Director-Health Innovation Accelerator, Health Innovation Manchester - an England's NHS organisation, UK will be participating and offering a unique perspective on the future of biotechnology. Some of the topics that will be addressed during the conference are ‘Accelerate Biotech Innovations and deliver biotech products for sustainable future under the session’, ‘Preparing for the next pandemic’, 'Biomanufacturing’ and ‘Advancing biologics product development’.
Hon’ble Union Minister of State (Independent Charge) Science & Technology, MoS PMO, Personnel, Public Grievances, Pensions, Atomic Energy and Space, Dr Jitendra Singh said “This event underscores India's imminent entry into the league of global leaders in biotechnology. The global significance of this event highlights the government's determination to attract international players to invest in India, fostering increased foreign direct investment in the pharmaceutical and biotech sectors. India is resolute in its commitment to assume a leadership role in the field of biotechnology”.
Dr Rajesh S Gokhale, Secretary, Department of Biotechnology (DBT) said, ‘Global Bio-India 2023 serves as a platform for innovation, where participants can explore, ideate and shape the future of the biotechnology industry. I believe this event will be a testament to our shared commitment to advancing science, improving lives and building a sustainable and inclusive future for all’.
Speaking about how the event is set to bring the global biotechnology industry together, Dr Jitendra Kumar, Managing Director, BIRAC said, ‘As we kick off Global Bio-India 2023, we envision a collaborative platform that offers an opportunity for all biotech stakeholders - from entrepreneurs and scientists to business and R&D professionals - come together to discuss the latest advancements in biotechnology. With the Indian biotech industry set to reach $150 billion by 2025 and an ambitious $300 billion by 2030, the event calls on individuals and companies worldwide to participate and establish innovative practices in a thriving market driven by escalating demand. It serves as a central point for international participants to share their thoughts on biotech innovations, biomanufacturing, AI and big data in life sciences and biotech, biopharma and emerging agri-technologies’ .
About DBT
The Department of Biotechnology (DBT), Ministry of Science and Technology, boosts and augments the development of biotechnology ecosystem in India, through its expansion and application in agriculture, healthcare, animal sciences, environment, and industry.
About BIRAC
Biotechnology Industry Research Assistance Council (BIRAC) is a not-for-profit Section 8, Schedule B, Public Sector Enterprise set up by Department of Biotechnology (DBT), Government of India, as an interface agency to strengthen and empower emerging biotech enterprises to undertake strategic research and innovation, addressing nationally relevant product development needs.
For Media Queries:
Contact Gutenberg at birac@thegutenberg.com
Innovations in Pharmaceutical Technology (IPT)
IPT provides a platform for cutting-edge ideas, concepts, and developments shaping the future of pharmaceutical R&D.